135 related articles for article (PubMed ID: 29465445)
1. Regorafenib-Associated Fatigue: A Systematic Review and Meta-analysis.
Invally M; Kanukula R; Salam MA; Shruthi G
Am J Ther; 2018; 25(6):e715-e717. PubMed ID: 29465445
[No Abstract] [Full Text] [Related]
2. Prophylactic Effect of Dexamethasone on Regorafenib-Related Fatigue and/or Malaise: A Randomized, Placebo-Controlled, Double-Blind Clinical Study in Patients with Unresectable Metastatic Colorectal Cancer (KSCC1402/HGCSG1402).
Tanioka H; Miyamoto Y; Tsuji A; Asayama M; Shiraishi T; Yuki S; Kotaka M; Makiyama A; Shimokawa M; Shimose T; Masuda S; Yamaguchi T; Komatsu Y; Saeki H; Emi Y; Baba H; Oki E; Maehara Y;
Oncology; 2018; 94(5):289-296. PubMed ID: 29514163
[TBL] [Abstract][Full Text] [Related]
3. Severe Maculopapular Exanthema Induced by Regorafenib: Successful Desensitization and Adaptation of a Dosage Regimen.
García-Gutiérrez I; Acevedo M; Tornero P; Matilla A; Márquez L; Sánchez-Herrero A; Prieto-García A
J Investig Allergol Clin Immunol; 2019 Aug; 29(4):300-302. PubMed ID: 31478526
[No Abstract] [Full Text] [Related]
4. Risk of hypertension with regorafenib in cancer patients: a systematic review and meta-analysis.
Wang Z; Xu J; Nie W; Huang G; Tang J; Guan X
Eur J Clin Pharmacol; 2014 Feb; 70(2):225-31. PubMed ID: 24150533
[TBL] [Abstract][Full Text] [Related]
5. Treatment-related serious adverse events and fatal adverse events with regorafenib in cancer patients: a meta-analysis of phase 3 randomized controlled trials.
Cao M; Li F; Wang Y; Zhang J
Invest New Drugs; 2017 Dec; 35(6):834-838. PubMed ID: 28936569
[TBL] [Abstract][Full Text] [Related]
6. A phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer.
Jones RL; Bendell JC; Smith DC; Diefenbach K; Lettieri J; Boix O; Lockhart AC; O'Bryant C; Moore KN
Cancer Chemother Pharmacol; 2015 Oct; 76(4):777-84. PubMed ID: 26281907
[TBL] [Abstract][Full Text] [Related]
7. Fatigue associated with newly approved vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: an up-to-date meta-analysis.
Li J; Gu J
Int J Clin Oncol; 2017 Oct; 22(5):807-816. PubMed ID: 28733794
[TBL] [Abstract][Full Text] [Related]
8. Prophylactic Use of Oral Dexamethasone to Alleviate Fatigue During Regorafenib Treatment for Patients With Metastatic Colorectal Cancer.
Fukuoka S; Shitara K; Noguchi M; Kawazoe A; Kuboki Y; Bando H; Okamoto W; Kojima T; Doi T; Ohtsu A; Yoshino T
Clin Colorectal Cancer; 2017 Jun; 16(2):e39-e44. PubMed ID: 27780748
[TBL] [Abstract][Full Text] [Related]
9. An update on the safety and efficacy of regorafenib in the treatment of solid cancers.
Chan SL; Ma BB
Expert Opin Drug Metab Toxicol; 2014 Nov; 10(11):1607-14. PubMed ID: 25316322
[TBL] [Abstract][Full Text] [Related]
10. Regorafenib: A Review in Hepatocellular Carcinoma.
Heo YA; Syed YY
Drugs; 2018 Jun; 78(9):951-958. PubMed ID: 29915898
[TBL] [Abstract][Full Text] [Related]
11. Regorafenib: start low and go slow.
Tabchi S; Ghosn M
Target Oncol; 2015 Sep; 10(3):445-7. PubMed ID: 25548130
[No Abstract] [Full Text] [Related]
12. Acute liver failure and seizures as a consequence of regorafenib exposure in advanced rectal cancer.
Raissouni S; Quraishi Z; Al-Ghamdi M; Monzon J; Tang P; Vickers MM
BMC Res Notes; 2015 Oct; 8():538. PubMed ID: 26438070
[TBL] [Abstract][Full Text] [Related]
13. Regorafenib for the treatment of unresectable hepatocellular carcinoma.
Rimassa L; Pressiani T; Personeni N; Santoro A
Expert Rev Anticancer Ther; 2017 Jul; 17(7):567-576. PubMed ID: 28580808
[TBL] [Abstract][Full Text] [Related]
14. Progression-free survival with regorafenib in gastric cancer.
Burki TK
Lancet Oncol; 2016 Aug; 17(8):e323. PubMed ID: 27375105
[No Abstract] [Full Text] [Related]
15. Regorafenib for cancer.
Strumberg D; Schultheis B
Expert Opin Investig Drugs; 2012 Jun; 21(6):879-89. PubMed ID: 22577890
[TBL] [Abstract][Full Text] [Related]
16. Regorafenib: Dress.
Prescrire Int; 2015 Jan; 24(156):20-1. PubMed ID: 25729832
[No Abstract] [Full Text] [Related]
17. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
Crona DJ; Keisler MD; Walko CM
Ann Pharmacother; 2013 Dec; 47(12):1685-96. PubMed ID: 24259629
[TBL] [Abstract][Full Text] [Related]
18. Regorafenib-induced hypothyroidism and cancer-related fatigue: is there a potential link?
Pani F; Massidda M; Pusceddu V; Puzzoni M; Massa E; Madeddu C; Scartozzi M; Mariotti S
Eur J Endocrinol; 2017 Jul; 177(1):85-92. PubMed ID: 28468766
[TBL] [Abstract][Full Text] [Related]
19. Regorafenib-induced hand-foot skin reaction with striking epidermal dysmaturation - a new histopathological pattern associated with the use of multi-kinase inhibitors.
Llamas-Velasco M; Hegyi I; Hesterberg U; Daudén E; Requena L; Kempf W
Br J Dermatol; 2016 Jul; 175(1):216-7. PubMed ID: 26801207
[No Abstract] [Full Text] [Related]
20. Investigation of Regorafenib-induced Hypothyroidism in Patients with Metastatic Colorectal Cancer.
Sugita K; Kawakami K; Yokokawa T; Mae Y; Toya W; Hagino A; Suzuki K; Suenaga M; Mizunuma N; Yamaguchi T; Hama T
Anticancer Res; 2015 Jul; 35(7):4059-62. PubMed ID: 26124355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
